Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EXEL

Exelixis Inc

May 22 • 04:00PM ET

50.15

+0.50 1.01 %

Healthcare • Biotechnology • USA • Large • NASD

Peers: INCY TGTX HALO LEGN KYMR ARVN SNDX IONS XNCR ROIV

| Held by: IJH VTI VB VBK VXF XMHQ XBI MDY IBB FBT

Scroll to Statements

Index	-	P/E	16.62	EPS (ttm)	3.02	Insider Own	2.84%	Shs Outstand	253.70M	Perf Week	0.04%
Market Cap	12.61B	Forward P/E	12.77	EPS next Y	3.93	Insider Trans	-8.65%	Shs Float	243.47M	Perf Month	8.90%
Enterprise Value	12.00B	PEG	0.97	EPS next Q	0.84	Inst Own	105.04%	Short Float	12.33%	Perf Quarter	13.95%
Income	833.42M	P/S	5.31	EPS this Y	13.42%	Inst Trans	2.15%	Short Ratio	10.73	Perf Half Y	19.01%
Sales	2.38B	P/B	6.57	EPS next Y	12.44%	ROA	30.69%	Short Interest	30.01M	Perf YTD	14.42%
Book/sh	7.63	P/C	16.22	EPS next 5Y	13.22%	ROE	40.99%	52W High	51.63 -2.87%	Perf Year	17.01%
Cash/sh	3.09	P/FCF	13.74	EPS past 3/5Y	70.35% 51.19%	ROIC	39.59%	52W Low	33.76 48.57%	Perf 3Y	153.67%
Dividend Est.	-	EV/EBITDA	12.17	Sales past 3/5Y	12.93% 18.63%	Gross Margin	96.44%	Volatility	2.33% 3.23%	Perf 5Y	105.03%
Dividend TTM	-	EV/Sales	5.05	EPS Y/Y TTM	38.64%	Oper. Margin	40.29%	ATR (14)	1.51	Perf 10Y	801.98%
Dividend Ex-Date	-	Quick Ratio	3.19	Sales Y/Y TTM	3.33%	Profit Margin	35.08%	RSI (14)	60.72	Recom	2.15
Dividend Gr. 3/5Y	- -	Current Ratio	3.26	EPS Q/Q	42.14%	SMA20	5.14%	Beta	0.40	Target Price	49.56
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	9.97%	SMA50	11.06%	Rel Volume	0.55	Prev Close	49.65
Employees	1077	LT Debt/Eq	0.09	Earnings	May 05 AMC	SMA200	18.70%	Avg Volume	2.80M	Price	50.15
IPO	Apr 11, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.77% 0.54%	Trades		Volume	1,542,699	Change	1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$48
Jan-05-26	Downgrade	BofA Securities	Neutral → Underperform	$41
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-21-25	Upgrade	Leerink Partners	Market Perform → Outperform	$48
Sep-19-25	Resumed	Barclays	Equal Weight	$40
Sep-17-25	Resumed	Barclays	Equal Weight	$40
Sep-17-25	Initiated	Goldman	Buy	$47
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$45 → $50
Jun-24-25	Upgrade	Stephens	Equal-Weight → Overweight	$60
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$36
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$30 → $40
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$36 → $40
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral	$35 → $39
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight	$25
Dec-19-23	Initiated	BTIG Research	Buy	$27
Dec-15-23	Initiated	Citigroup	Buy	$31

Show Previous Ratings

May-21-26 05:00PM	Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types (Business Wire)
May-19-26 08:00AM	Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer (Business Wire)
May-07-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May (Business Wire) -5.11%
May-05-26 08:17PM	Exelixis, Inc. Q1 2026 Earnings Call Summary (Moby) +9.64%
04:13PM	Exelixis: Q1 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update (Business Wire)
Apr-21-26 04:05PM	Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 (Business Wire) +5.23%
02:20PM	Why Dow Jones Stock Merck Skidded 4% - And Boosted A Key Rival (Investor's Business Daily)
Mar-30-26 07:52AM	Lillys AI commitment expands through deal with Insilico (BioPharma Dive)
Mar-02-26 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks) -6.88%
Feb-24-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March (Business Wire)
10:58AM	Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge (PR Newswire)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Feb-20-26 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
Feb-18-26 10:50AM	Expand Energy Q4 Earnings Call Highlights (MarketBeat)
09:15AM	Loading…
Feb-16-26 09:15AM	A Dive into Exelixis (EXEL) International Revenue Trends and Forecasts (Zacks)
Feb-13-26 10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:20AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Feb-12-26 12:40PM	Exelixis Reports Solid Earnings-Are New Highs Back on the Table? (MarketBeat)
11:40AM	EXEL or LQDA: Which Is the Better Value Stock Right Now? (Zacks)
10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-11-26 10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
08:30AM	Exelixis, Inc. Q4 2025 Earnings Call Summary (Moby)
12:01AM	Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-10-26 07:30PM	Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics (Zacks)
07:29PM	Exelixis Q4 Earnings Call Highlights (MarketBeat)
05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:22PM	Loading…
04:22PM	Exelixis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update (Business Wire)
09:32AM	4 Discounted PEG Value Stocks to Boost Your Portfolio's Health (Zacks)
06:41AM	Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In (Insider Monkey)
Feb-09-26 07:12PM	2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD (Zacks)
11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-05-26 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) (Zacks)
10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-04-26 09:45AM	Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Feb-03-26 10:00AM	Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
09:40AM	Should Value Investors Buy Exelixis (EXEL) Stock? (Zacks)
Feb-02-26 08:00AM	Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer (Business Wire)
Jan-31-26 07:13PM	2 Stocks That Could Soar This Year (Motley Fool)
Jan-28-26 05:42AM	Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies (Pharmaceutical Technology)
Jan-27-26 04:05PM	Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 (Business Wire)
11:40AM	EXEL vs. EXAS: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Jan-20-26 04:59AM	Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch (Insider Monkey)
Jan-15-26 03:01PM	Exelixis, Inc. (EXEL): A Bull Case Theory (Insider Monkey)
09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-14-26 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-12-26 09:33AM	Exelixis Posts Preliminary '25 Results, Issues '26 Outlook (Zacks)
Jan-11-26 04:00PM	Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 (Business Wire)
Jan-09-26 05:18PM	Signet Jewelers, Natural Gas Services, and More Stocks See Action From Activist Investors (Barrons.com)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks)
05:35AM	2 Healthcare Stocks to Buy for 2026 and Beyond (Motley Fool)
Jan-07-26 08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire) +5.75%
Jan-06-26 04:05PM	Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 (Business Wire)
Jan-03-26 07:20AM	Klaviyo, Wingstop among Stephens Best Ideas for 2026 (TipRanks)
Dec-31-25 12:46PM	See How Rare Bullish Inflows Lift Outliers Like Exelixis (FX Empire)
09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
Dec-30-25 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-18-25 02:19PM	Exelixis Near A Buy Point. Relative Strength Rating Climbs. (Investor's Business Daily)
09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Dec-15-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
Dec-04-25 11:30AM	Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-03-25 04:05PM	Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 (Business Wire)
Dec-02-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-01-25 08:06PM	2 Under-the-Radar Stocks to Buy Heading Into 2026 (Motley Fool)
Nov-28-25 09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
Nov-17-25 09:15AM	Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention (Zacks)
Nov-13-25 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Nov-12-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-11-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
Nov-06-25 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November (Business Wire)
04:56AM	Company News for Nov 6, 2025 (Zacks)
Nov-05-25 10:52AM	EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales (Zacks) +6.52%
12:08AM	Exelixis Inc (EXEL) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-04-25 06:30PM	Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:55PM	Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:55PM	Exelixis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
Oct-29-25 10:00AM	Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-28-25 12:24PM	Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners (Insider Monkey)
10:00AM	Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:01AM	Merck kidney cancer drug succeeds in two large trials (BioPharma Dive)
Oct-27-25 12:10PM	Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Oct-21-25 04:05PM	Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (Business Wire)
12:54PM	Exelixis (EXEL) Loses 12% on Cancer Treatment Trial Results (Insider Monkey)
09:32AM	Goldman downgraded, Coinbase initiated: Wall Street's top analyst calls (The Fly)
Oct-20-25 05:01AM	Exelixis shares dip on colorectal cancer data (BioPharma Dive) -12.00%
02:30AM	Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet (Business Wire)
Oct-18-25 03:00AM	Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 (Business Wire)
Oct-14-25 07:30AM	The Ultimate Biotech Stock to Buy With $50 Right Now (Motley Fool)
Oct-09-25 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Oct-08-25 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)

Exelixis, Inc.. The Group's principal activity is to develop innovative therapies for cancer and other serious diseases. Its pharmaceutical programs focuses on discovery and development of small molecule drugs for cancer. The Gruoup has built a multidisciplinary, integrated research and development platform that supports the complex, iterative nature of drug discovery, translational research and clinical development. Its first-generation anticancer product candidates in our clinical pipeline are Spectrum Selective Kinase Inhibitors, that have been optimized for balanced potency, specificity, tolerability and pharmacologic parameters. It operates in the United States.

Co-Founder & Independent Chair of the BoardDr. Stelios Papadopoulos Ph.D.

CEODr. Michael M. Morrissey Ph.D.

Executive VP & CFOMr. Christopher J. Senner

Ph.D.Dr. Brenda J. Hefti J.D.

Executive Vice President of Research & DevelopmentDr. Dana T. Aftab Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haley Patrick J.	EVP, Commercial	May 20 '26	Sale	49.81	32,110	1,599,399	357,638	May 22 05:01 PM
PATRICK JOSEPH HALEY	Officer	May 20 '26	Proposed Sale	49.81	32,110	1,599,444		May 20 04:31 PM
Senner Christopher J.	EVP and CFO	May 18 '26	Sale	50.00	34,901	1,745,050	952,317	May 19 06:58 PM
Hefti Brenda	SVP and General Counsel	May 18 '26	Sale	50.21	6,625	332,641	106,762	May 19 06:58 PM
CHRISTOPHER J SENNER	Officer	May 18 '26	Proposed Sale	50.00	34,901	1,745,179		May 18 04:49 PM
BRENDA JOY HEFTI	Officer	May 18 '26	Proposed Sale	50.21	6,625	332,641		May 18 04:23 PM
BOMBORA RISE FOUNDATION	Family foundation of the CEO o	May 14 '26	Proposed Sale	50.91	100,000	5,091,190		May 14 04:30 PM
Beckerle Mary C	Director	May 07 '26	Option Exercise	23.24	3,856	89,613	25,236	May 08 07:03 PM
Beckerle Mary C	Director	May 07 '26	Sale	48.45	7,712	373,646	17,524	May 08 07:03 PM
Freire Maria C	Director	May 07 '26	Option Exercise	19.77	20,634	407,934	121,453	May 08 07:03 PM
Freire Maria C	Director	May 07 '26	Sale	46.00	20,634	949,164	100,819	May 08 07:03 PM
POSTE GEORGE	Director	May 07 '26	Sale	45.71	60,000	2,742,600	118,832	May 08 07:03 PM
MARY BECKERLE	Director	May 07 '26	Proposed Sale	48.45	7,712	373,646		May 07 04:39 PM
GEORGE H POSTE	Director	May 07 '26	Proposed Sale	45.71	60,000	2,742,468		May 07 04:36 PM
MARIA C FREIRE	Director	May 07 '26	Proposed Sale	46.00	20,634	949,164		May 07 04:07 PM
Aftab Dana	EVP, Research and Development	Feb 24 '26	Sale	44.50	47,918	2,132,351	616,106	Feb 26 06:41 PM
DANA T AFTAB	Officer	Feb 24 '26	Proposed Sale	44.50	47,918	2,132,351		Feb 24 04:05 PM
Aftab Dana	EVP, Research and Development	Feb 19 '26	Sale	44.35	29,873	1,324,868	664,024	Feb 23 06:50 PM
WYSZOMIERSKI JACK L	Director	Feb 18 '26	Option Exercise	19.77	20,634	407,934	379,516	Feb 20 08:36 PM
WYSZOMIERSKI JACK L	Director	Feb 18 '26	Sale	44.01	99,574	4,382,252	279,942	Feb 20 08:36 PM
Smith Julie	Director	Feb 18 '26	Option Exercise	20.11	64,117	1,289,298	64,677	Feb 19 07:18 PM
Smith Julie	Director	Feb 17 '26	Option Exercise	18.19	42,422	771,656	63,012	Feb 19 07:18 PM
Smith Julie	Director	Feb 18 '26	Sale	44.44	64,117	2,849,200	20,590	Feb 19 07:18 PM
Smith Julie	Director	Feb 17 '26	Sale	43.33	42,422	1,838,145	20,590	Feb 19 07:18 PM
DANA T AFTAB	Officer	Feb 19 '26	Proposed Sale	44.35	29,873	1,324,868		Feb 19 04:06 PM
Senner Christopher J.	EVP and CFO	Feb 13 '26	Sale	43.00	34,278	1,473,954	1,042,579	Feb 18 08:49 PM
Senner Christopher J.	EVP and CFO	Feb 17 '26	Sale	43.67	30,617	1,337,044	976,092	Feb 18 08:49 PM
Haley Patrick J.	EVP, Commercial	Feb 17 '26	Sale	43.52	67,814	2,950,941	381,908	Feb 18 08:49 PM
MORRISSEY MICHAEL	President and CEO	Feb 13 '26	Option Exercise	21.31	494,700	10,542,057	2,319,941	Feb 18 08:49 PM
Eckhardt Sue Gail	Director	Feb 13 '26	Sale	43.79	3,856	168,854	17,524	Feb 18 08:49 PM
Oliver Bob	Director	Feb 13 '26	Option Exercise	19.28	9,088	175,217	51,370	Feb 18 08:48 PM
Oliver Bob	Director	Feb 13 '26	Sale	43.81	30,250	1,325,339	21,120	Feb 18 08:48 PM
Hefti Brenda	SVP and General Counsel	Feb 18 '26	Sale	44.01	18,669	821,623	96,512	Feb 18 08:48 PM
JULIE ANNE SMITH	Director	Feb 18 '26	Proposed Sale	44.44	64,117	2,849,200		Feb 18 05:55 PM
BRENDA JOY HEFTI	Officer	Feb 18 '26	Proposed Sale	44.01	18,669	821,664		Feb 18 04:30 PM
JACK L WYSZOMIERSKI	Director	Feb 18 '26	Proposed Sale	44.01	99,574	4,382,507		Feb 18 04:01 PM
JULIE ANNE SMITH	Director	Feb 17 '26	Proposed Sale	44.33	42,422	1,880,440		Feb 17 06:47 PM
CHRISTOPHER J SENNER	Officer	Feb 17 '26	Proposed Sale	43.67	30,617	1,337,035		Feb 17 06:45 PM
PATRICK JOSEPH HALEY	Officer	Feb 17 '26	Proposed Sale	43.52	67,814	2,951,083		Feb 17 06:43 PM
Eckhardt Sue Gail	Director	Feb 13 '26	Proposed Sale	42.89	3,856	165,384		Feb 13 04:39 PM
CHRISTOPHER J SENNER	Officer	Feb 13 '26	Proposed Sale	43.00	34,278	1,473,964		Feb 13 04:07 PM
ROBERT L OLIVER	Director	Feb 13 '26	Proposed Sale	43.82	30,250	1,325,408		Feb 13 04:07 PM
BOMBORA RISE FOUNDATION	Family foundation of the CEO o	Feb 12 '26	Proposed Sale	43.25	5,000	216,250		Feb 12 07:02 PM
Haley Patrick J.	Officer	Nov 20 '25	Proposed Sale	41.78	10,648	444,873		Dec 12 06:08 PM
JOHNSON DAVID EDWARD	Director	Nov 25 '25	Buy	43.12	27,532	1,187,235	1,553,262	Nov 26 04:05 PM
Haley Patrick J.	EVP, Commercial	Nov 20 '25	Sale	41.88	34,187	1,431,757	0	Nov 24 07:47 PM
Haley Patrick J.	EVP, Commercial	Nov 21 '25	Sale	42.58	28,043	1,194,071	374,029	Nov 24 07:47 PM
Haley Patrick J.	EVP, Commercial	Nov 20 '25	Sale	42.11	10,000	421,100	402,072	Nov 24 07:47 PM
PATRICK JOSEPH HALEY	Officer	Nov 20 '25	Proposed Sale	42.11	10,000	421,052		Nov 20 04:02 PM
PAPADOPOULOS STELIOS	Director	Nov 12 '25	Sale	43.55	100,000	4,355,000	1,189,228	Nov 13 07:12 PM
Aftab Dana	EVP, Research and Development	Nov 11 '25	Sale	42.50	48,383	2,056,278	664,778	Nov 13 07:12 PM
Beckerle Mary C	Director	Nov 11 '25	Option Exercise	23.24	5,784	134,420	46,002	Nov 13 07:12 PM
Beckerle Mary C	Director	Nov 11 '25	Sale	41.93	24,622	1,032,414	21,380	Nov 13 07:12 PM
JEFFREY J HESSEKIEL	Officer	Nov 13 '25	Proposed Sale	43.15	40,000	1,726,128		Nov 13 04:11 PM
Stelios Papadopoulos	Director	Nov 12 '25	Proposed Sale	43.55	100,000	4,355,204		Nov 12 05:41 PM
JEFFREY J HESSEKIEL	Officer	Nov 12 '25	Proposed Sale	43.02	60,000	2,581,006		Nov 12 04:16 PM
DANA T AFTAB	Officer	Nov 11 '25	Proposed Sale	42.50	48,383	2,056,360		Nov 12 10:30 AM
MARY BECKERLE	Director	Nov 11 '25	Proposed Sale	41.93	24,622	1,032,436		Nov 12 09:10 AM
Eckhardt Sue Gail	Director	Jun 02 '25	Sale	42.74	18,838	805,140	21,380	Jun 04 07:57 PM
WYSZOMIERSKI JACK L	Director	Jun 03 '25	Sale	43.09	7,535	324,683	358,882	Jun 04 07:57 PM
JACK L WYSZOMIERSKI	Director	Jun 03 '25	Proposed Sale	43.09	7,535	324,658		Jun 03 04:04 PM
Eckhardt Sue Gail	Director	Jun 02 '25	Proposed Sale	43.54	18,838	820,206		Jun 02 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXEL

Exelixis Inc

Upgrade your Finviz experience